(CIANEWS) - The Czech Ministry of Health (MZe) and Pfizer have concluded a contract for the supply of the oral antiviral Paxlovid against COVID-19. The contract, which runs until the end of 2022, ensures that the Czech Republic will have sufficient quantities of the drug for the expected autumn wave. The first deliveries are expected during September. Minister Vlastimil Válek (TOP 09) said that the Ministry of Health will soon offer Czech patients another fully reimbursed and highly effective antiviral drug.